TriStar Bone Marrow Transplant, LLC
Welcome,         Profile    Billing    Logout  
 11 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Weiss, Daniel
NCT02633644: Endovascular NeuromoDulation Treatment fOr Heart Failure Patients (ENDO-HF)

Terminated
2
30
Europe, RoW
Harmony System
Enopace Biomedical
Heart Failure
06/23
 
SGR-1505-101, NCT05544019: Study of SGR-1505 in Mature B-Cell Neoplasms

Recruiting
1
52
US, RoW
SGR-1505
Schrödinger, Inc.
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
03/26
03/26
SGR-2921-101, NCT05961839: Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recruiting
1
50
US
SGR-2921
Schrödinger, Inc.
Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
12/25
12/25
SANTOP, NCT03548506: Subthalamic Steering for Therapy Optimization in Parkinson's Disease

Active, not recruiting
N/A
20
Europe
Omnidirectional Deep Brain Stimulation of STN, Directional Deep Brain Stimulation of STN
University Hospital Tuebingen, Abbott
Parkinson Disease
12/21
04/22
NCT05579379: DESENSITIZE-PD: Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Support Dopaminergic Desensitization in PD

Not yet recruiting
N/A
20
NA
University Hospital Tuebingen, STADAPHARM GmbH
Parkinson Disease
09/24
09/24
NCT06498349: Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl

Recruiting
N/A
60
Europe
bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment, best medical treatment for management of impulse control in Parkinson´s disease, best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations
University of Kiel, Insel Gruppe AG, University Hospital Bern, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), Philipps University Marburg Medical Center, University Hospital Schleswig-Holstein, Campus Kiel, Czech Technical University in Prague, University of Pennsylvania
Parkinson Disease, Impulse Control Disorders
07/27
07/28
NCT06561919: STIMPulseControl Ancillary Speech Study

Recruiting
N/A
60
Europe
bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper, best medical treatment for manangement of impulse control in Parkinson´s disease, best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper
Steffen Paschen, Czech Technical University in Prague, Insel Gruppe AG, University Hospital Bern, Philipps University Marburg Medical Center, University Hospital Schleswig-Holstein, Campus Kiel, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Parkinson Disease, Impulse Control Disorder
07/27
07/28
Bachier, Carlos
NCT03436862: Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Completed
2
37
US
Nivolumab, Opdivo
SCRI Development Innovations, LLC, Bristol-Myers Squibb
Hodgkin Lymphoma
05/22
04/23
NCT04450069: CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Completed
1
18
US
CLBR001 and SWI019
Calibr, a division of Scripps Research
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma, Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma
05/24
05/24
NKX101-101, NCT04623944: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Active, not recruiting
1
61
US
NKX101 - CAR NK cell therapy, Cyclophosphamide, Fludarabine, Cytarabine (ara-C), Decitabine
Nkarta, Inc.
Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
10/24
07/39
Strickland, Steven
SGR-2921-101, NCT05961839: Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recruiting
1
50
US
SGR-2921
Schrödinger, Inc.
Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
12/25
12/25
Hanna, Nardin
AMpLify, NCT06128044: CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
70
US
CB-012, Cyclophosphamide, Fludarabine
Caribou Biosciences, Inc.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
11/27
04/28

Download Options